NO310126B1 - Initiator for bestemmelse av koaguleringstid, reagens for bestemmelse av aPTT, fremgangsmåte ved fremstilling av reagensetog anvendelse derav - Google Patents
Initiator for bestemmelse av koaguleringstid, reagens for bestemmelse av aPTT, fremgangsmåte ved fremstilling av reagensetog anvendelse derav Download PDFInfo
- Publication number
- NO310126B1 NO310126B1 NO931774A NO931774A NO310126B1 NO 310126 B1 NO310126 B1 NO 310126B1 NO 931774 A NO931774 A NO 931774A NO 931774 A NO931774 A NO 931774A NO 310126 B1 NO310126 B1 NO 310126B1
- Authority
- NO
- Norway
- Prior art keywords
- reagent
- coagulation
- plasma
- aptt
- phospholipids
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 105
- 230000015271 coagulation Effects 0.000 title claims abstract description 56
- 238000005345 coagulation Methods 0.000 title claims abstract description 56
- 239000003999 initiator Substances 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 3
- 210000002381 plasma Anatomy 0.000 claims abstract description 51
- 239000005995 Aluminium silicate Substances 0.000 claims abstract description 32
- 235000012211 aluminium silicate Nutrition 0.000 claims abstract description 32
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 32
- 239000012190 activator Substances 0.000 claims abstract description 24
- 239000007787 solid Substances 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 210000004369 blood Anatomy 0.000 claims abstract description 13
- 239000008280 blood Substances 0.000 claims abstract description 13
- 239000003914 blood derivative Substances 0.000 claims abstract description 12
- 229920000209 Hexadimethrine bromide Polymers 0.000 claims description 20
- 230000004913 activation Effects 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 230000035945 sensitivity Effects 0.000 claims description 14
- 108090000778 Platelet factor 4 Proteins 0.000 claims description 11
- 102000004211 Platelet factor 4 Human genes 0.000 claims description 11
- 238000007792 addition Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 7
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 7
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 6
- 229910001424 calcium ion Inorganic materials 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 5
- 108010022901 Heparin Lyase Proteins 0.000 claims description 5
- 229920001499 Heparinoid Polymers 0.000 claims description 5
- 108010000499 Thromboplastin Proteins 0.000 claims description 5
- 102000002262 Thromboplastin Human genes 0.000 claims description 5
- 239000002554 heparinoid Substances 0.000 claims description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 102000007327 Protamines Human genes 0.000 claims description 4
- 108010007568 Protamines Proteins 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 229940048914 protamine Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- 239000003593 chromogenic compound Substances 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 24
- 229920000669 heparin Polymers 0.000 description 24
- 229960002897 heparin Drugs 0.000 description 24
- 108010054218 Factor VIII Proteins 0.000 description 15
- 102000001690 Factor VIII Human genes 0.000 description 15
- 229960000301 factor viii Drugs 0.000 description 14
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 238000005259 measurement Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 4
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 4
- 229920002079 Ellagic acid Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229960002852 ellagic acid Drugs 0.000 description 4
- 235000004132 ellagic acid Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 102000000429 Factor XII Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001250090 Capra ibex Species 0.000 description 1
- 206010067787 Coagulation factor deficiency Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 208000014763 coagulation protein disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/04—Phospholipids, i.e. phosphoglycerides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT99892A AT398983B (de) | 1992-05-15 | 1992-05-15 | Reagens zur bestimmung der aptt |
| AT84193A AT402074B (de) | 1993-04-30 | 1993-04-30 | Reagens zur bestimmung der aptt |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO931774D0 NO931774D0 (no) | 1993-05-14 |
| NO931774L NO931774L (no) | 1993-11-16 |
| NO310126B1 true NO310126B1 (no) | 2001-05-21 |
Family
ID=25594074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO931774A NO310126B1 (no) | 1992-05-15 | 1993-05-14 | Initiator for bestemmelse av koaguleringstid, reagens for bestemmelse av aPTT, fremgangsmåte ved fremstilling av reagensetog anvendelse derav |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0570356B1 (hu) |
| JP (1) | JPH0643169A (hu) |
| AT (1) | ATE176822T1 (hu) |
| CA (1) | CA2096212A1 (hu) |
| CZ (1) | CZ87993A3 (hu) |
| DE (1) | DE59309374D1 (hu) |
| DK (1) | DK0570356T3 (hu) |
| ES (1) | ES2130244T3 (hu) |
| FI (1) | FI932195A (hu) |
| HU (1) | HU216882B (hu) |
| MX (1) | MX9302831A (hu) |
| NO (1) | NO310126B1 (hu) |
| SK (1) | SK48793A3 (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4337278C2 (de) * | 1993-11-02 | 1996-09-05 | Wolf Dr Bertling | Kit zur individuellen Kontrolle einer Antikoagulantientherapie |
| GR1002776B (el) * | 1996-12-02 | 1997-09-26 | . | Εξουδετερωση της αντιπηκτικης δρασης του συμπλεγματος της αντιθρομβινης-ιιι/ ηπαρινης, νεα δοκιμασια αποκαλυψης θρομβοφιλικων καταστασεων |
| AT405692B (de) * | 1997-03-27 | 1999-10-25 | Immuno Ag | Reagens zur bestimmung der aptt |
| DE60011274T2 (de) | 1999-09-03 | 2005-07-07 | Roche Diagnostics Corp., Indianapolis | Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit |
| US6448024B1 (en) | 2000-10-03 | 2002-09-10 | Roche Diagnostics Corporation | Method, reagent, cartridge, and device for determining fibrinogen |
| JP2011133396A (ja) * | 2009-12-25 | 2011-07-07 | Sysmex Corp | 活性化部分トロンボプラスチン時間測定試薬、活性化部分トロンボプラスチン時間測定方法、及び血液凝固抑制物質の有無の判定方法 |
| CN107356768A (zh) * | 2017-06-23 | 2017-11-17 | 宁波艾科生物科技有限公司 | 一种液体即用型凝血酶原时间检测试剂 |
| CN107356769A (zh) * | 2017-06-23 | 2017-11-17 | 宁波艾科生物科技有限公司 | 一种液体即用型活化部分凝血活酶时间的检测试剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1213198A (en) * | 1982-09-29 | 1986-10-28 | James E. Hughes | Diagnostic activated partial thromboplastin reagent |
| DE3311287A1 (de) * | 1983-03-28 | 1984-10-04 | Behringwerke Ag, 3550 Marburg | Verfahren zur fotometrischen bestimmung der aktivierten partiellen thromboplastinzeit und reagenz dazu |
| CH678892A5 (en) * | 1989-04-04 | 1991-11-15 | Pentapharm Ag | Heparin-sensitive reagent for measuring activated thromboplastin - contains cephalin, sulphate and additive, e.g. lidocaine, modifying sensitivity to heparin or lupus anticoagulant |
| ATE140034T1 (de) * | 1990-04-17 | 1996-07-15 | Analytical Control Syst Inc | Koagulationsassays und reagenzien |
| US5314695A (en) * | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
-
1993
- 1993-05-12 EP EP93890099A patent/EP0570356B1/de not_active Expired - Lifetime
- 1993-05-12 DE DE59309374T patent/DE59309374D1/de not_active Expired - Fee Related
- 1993-05-12 DK DK93890099T patent/DK0570356T3/da not_active Application Discontinuation
- 1993-05-12 ES ES93890099T patent/ES2130244T3/es not_active Expired - Lifetime
- 1993-05-12 AT AT93890099T patent/ATE176822T1/de not_active IP Right Cessation
- 1993-05-12 CZ CZ93879A patent/CZ87993A3/cs unknown
- 1993-05-13 CA CA002096212A patent/CA2096212A1/en not_active Abandoned
- 1993-05-14 SK SK487-93A patent/SK48793A3/sk unknown
- 1993-05-14 HU HU9301400A patent/HU216882B/hu not_active IP Right Cessation
- 1993-05-14 FI FI932195A patent/FI932195A/fi unknown
- 1993-05-14 JP JP5112783A patent/JPH0643169A/ja active Pending
- 1993-05-14 MX MX9302831A patent/MX9302831A/es unknown
- 1993-05-14 NO NO931774A patent/NO310126B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2130244T3 (es) | 1999-07-01 |
| HU9301400D0 (en) | 1993-09-28 |
| NO931774D0 (no) | 1993-05-14 |
| FI932195A (fi) | 1993-11-16 |
| JPH0643169A (ja) | 1994-02-18 |
| EP0570356A1 (de) | 1993-11-18 |
| DK0570356T3 (da) | 1999-09-20 |
| SK48793A3 (en) | 1993-12-08 |
| HU216882B (hu) | 1999-09-28 |
| ATE176822T1 (de) | 1999-03-15 |
| MX9302831A (es) | 1994-05-31 |
| CA2096212A1 (en) | 1993-11-16 |
| CZ87993A3 (en) | 1994-02-16 |
| NO931774L (no) | 1993-11-16 |
| FI932195A0 (fi) | 1993-05-14 |
| EP0570356B1 (de) | 1999-02-17 |
| DE59309374D1 (de) | 1999-03-25 |
| HUT75667A (en) | 1997-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lundblad et al. | The activation of antihemophilic factor (factor VIII) by activated Christmas factor (activated factor IX) | |
| Bergström et al. | Determination of vitamin K sensitive coagulation factors in plasma. Studies on three methods using synthetic chromogenic substrates | |
| JP5640189B2 (ja) | ループスアンチコアグラント検出用血液凝固時間の測定方法 | |
| Barton et al. | The preparation and properties of a stable factory V from bovine plasma | |
| EA000673B1 (ru) | Анализ крови на соотношение активности фактора v для оценки вероятности заболевания тромбоэмболией | |
| US4946775A (en) | Composition, kit and method for assaying heparin and a method for making the composition | |
| NO310126B1 (no) | Initiator for bestemmelse av koaguleringstid, reagens for bestemmelse av aPTT, fremgangsmåte ved fremstilling av reagensetog anvendelse derav | |
| US5506112A (en) | Reagent used for determining factor VIII activity | |
| NO161079B (no) | Reagens for optisk bestemmelse av blodkoaguleringsforholdet. | |
| US4948724A (en) | Composition, kit and method for assaying heparin and a method for making the composition | |
| Johnston et al. | Development of increased factor VII activity during the spontaneous coagulation of blood | |
| CA2244654C (en) | Use of annexins as a lupus anticoagulant control or standard in clotting tests | |
| JPH05180835A (ja) | ループスアンチコアグラントの測定方法 | |
| Guglielmone et al. | A Novel Functional Assay of Protein C in Human Plasma and fts Comparison with Amidolytic and Anticoagulant Assays | |
| CA2039173C (en) | Factor ix chromogenic assay | |
| CA2065370C (en) | Factor viii:ca chromogenic assay | |
| Chuansumrit et al. | Heparin cofactor II in adults and infants with thrombosis and DIC | |
| EP0841566A1 (en) | Positive control plasma for lupus anticoagulant | |
| EP0217768B1 (en) | Method and compositions for heparin assays | |
| US5476771A (en) | Test for quantitative thrombin time | |
| Barthels et al. | Acquired thrombin inhibitor in a patient with liver cirrhosis | |
| CA2137342A1 (en) | Test for quantitative thrombin time | |
| Yamada et al. | A new APTT assay employing a chromogenic substrate and a centrifugal autoanalyzer | |
| EP0561780B1 (en) | Lipid-dependent diagnostic assays | |
| Hellstern et al. | Determination of factor XIII activity and of factor XIII inhibitors using an ammonium-sensitive electrode |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |